Exhibit 99.1
DTHERA
SCIENCES RECEIVES FDA BREAKTHROUGH DEVICE DESIGNATION FOR ITS ALZHEIMER’S FOCUSED DEVELOPMENT-STAGE PRODUCT “DTHR-ALZ”
SAN DIEGO, CA. August 23, 2018 - Dthera™ Sciences
(OTCQB:DTHR), the leading digital therapeutic company focusing on the elderly and individuals with neurodegenerative diseases,
announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to the Company’s
development-stage product, DTHR-ALZ.
DTHR-ALZ, if granted approval, would become the first non-pharmacological
prescription treatment for the symptoms of Alzheimer’s disease. The proposed indication for use states that “DTHR-ALZ
is intended to mitigate the symptoms of agitation and depression associated with major neurocognitive disorder of the Alzheimer's
type.” To the Company’s knowledge, Dthera Sciences is only the second digital therapeutics company to obtain Breakthrough
Device designation from the FDA.
“Alzheimer’s disease is a significant and rapidly
growing public health crisis, and, among the 10 leading causes of death in the U.S., it is the only one that cannot be prevented,
cured or slowed,” said Edward Cox, CEO of Dthera Sciences, a publicly traded company based in San Diego. “We commend
the FDA for recognizing this significant unmet medical need as well as the critical importance of providing innovative new treatments
to patients with Alzheimer’s and their caregivers. While we feel this ground-breaking recognition validates Dthera’s
mission to positively impact the lives of those effected by the disease, it also represents a meaningful advance for the entire
digital therapeutic sector.”
Under the Breakthrough Devices program, a provision of the 21st
Century Cures Act, the FDA works with medical device developers to expedite regulatory review in order to give patients more timely
access to diagnostic and therapeutic technologies. According to the FDA, a “Breakthrough Device” is a product that
may be more effective at treating or diagnosing a life-threatening or irreversibly debilitating disease or condition compared to
the current standard of care.
DTHR-ALZ is intended to be a prescription digital therapeutic
that will deliver Reminiscence Therapy to patients with Alzheimer’s disease. The device will use artificial intelligence
to automatically optimize the therapy based on various forms of biofeedback from the patient. According to the Alzheimer’s
Association, Reminiscence Therapy is an evidence-based psychosocial intervention that has been shown in clinical trials to improve
symptoms of the disorder, but the therapy’s adoption has been limited because of the investment of caregiver time and resources.
DTHR-ALZ, however, will seek to provide Reminiscence Therapy with more frequency, consistency and personalization while requiring
minimal investment of time and resources.
Alzheimer’s disease affects about 5.7 million people in
the U.S. today, according to the Alzheimer’s Association. With the aging population and few therapeutic options on the horizon,
the impact of Alzheimer’s disease is only expected to grow. The cost of care for dementia patients is predicted to increase
from $277 billion in 2018 to more than $1.1 trillion by 2050.
“This Breakthrough designation has provided us with a
remarkable opportunity to expedite the development of our digital therapeutic device,” said Martin Culjat, Ph.D., VP of Scientific
and Regulatory Affairs at Dthera Sciences. “We feel deeply honored that the FDA has confirmed DTHR-ALZ meets the requirements
for this designation, and we are eager to work together with the FDA throughout this process.”
DTHR-ALZ is not yet available for commercial use in the U.S.
About Dthera Sciences:
Dthera Sciences (OTCQB:DTHR) is the leading digital therapeutic
company focusing on the elderly and individuals with neurodegenerative diseases. The San Diego-based, publicly traded company has
two core products: ReminX™, a commercially available consumer health product for individuals suffering from social isolation
and dementia; and DTHR-ALZ, a development-stage product that has been granted Breakthrough Device designation by the FDA for the
mitigation of the symptoms of agitation and depression associated with Alzheimer’s disease.
Forward Looking Statements:
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking
words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,”
and “intend,” among others. These forward-looking statements are based on Dthera’s current expectations and actual
results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated
by such forward-looking statements. These factors include, but are not limited to, substantial competition; our need for additional
financing; uncertainties of intellectual property and patent protection; uncertainties of government or third party payor reimbursement;
limited research and development efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances
or approvals and noncompliance with FDA regulations. As with any digital therapeutic technology under development, there are significant
risks in the development, regulatory approval and commercialization of new products. Dthera expressly disclaims any obligation
to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form
10-K for the year ended December 31, 2017, as filed with the Securities and Exchange Commission (the “SEC”), and future
periodic reports filed with the SEC on or after the date hereof. All of Dthera’s forward-looking statements are expressly
qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date
hereof.
Contacts:
Company Contact
Geno Kostikov, Corporate Development
Dthera Sciences
geno@dthera.com
(858) 215-5597
Media Relations
Joice Truban Curry, Publicist
c3 Communications, Inc.
joice@c3publicrelations.com
(858) 794-6974
Investor Relations
Marek Ciszewski, J.D., Managing Director, Head of Life Sciences
Liolios
DTHR@Liolios.com
(949) 574-38600
